Business
Aeterna Zentaris to Present at Upcoming 10th Annual JMP Securities Research Conference in San Francisco
May 4, 2011 (Canada NewsWire Group) -- QUÉBEC CITY, May 4 2011 /CNW Telbec/ - Aeterna Ze...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n May 4, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nQUÉBEC CITY, May 4 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the "Company") today announced that its President and\n CEO, Juergen Engel, Ph.D., will make a corporate presentation at the\n upcoming 10th Annual JMP Securities Research Conference on Wednesday, May 11, 2011,\n at 1:00 p.m. (Pacific time) in Salon II of the Ritz Carlton Hotel in\n San Francisco, California.\n\n\nA live webcast of the presentation will be available on Aeterna\n Zentaris' website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be\n available on the Company's website for a period of 90 days.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a late-stage oncology drug development company\n currently investigating potential treatments for various cancers\n including colorectal, ovarian, endometrial cancer and multiple myeloma.\n The Company's innovative approach of "personalized medicine" means\n tailoring treatments to a patient's specific condition and to unmet\n medical needs. Aeterna Zentaris' deep pipeline is drawn from its\n proprietary discovery unit providing the Company with constant and\n long-term access to state-of-the-art therapeutic options. For more\n information please visit www.aezsinc.com.\n\n\n\n\n Investor Relations Ginette Vallières Investor Relations Coordinator (418) 652-8525 ext. 265 [email protected] Erika Moran ...